Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria

Jane Quinn, Stuart McCarthy

Research output: Contribution to journalLetterpeer-review

2 Downloads (Pure)

Abstract

To the Editor: Cytochrome P-450 2D6 (CYP2D6) screening has been used to improve the safety and efficacy of primaquine to prevent the clinical relapse of Plasmodium vivax malaria on the recommendation of the Centers for Disease Control and Prevention.1 Tafenoquine, a primaquine analogue, requires CYP2D6-mediated metabolic activation for antimalarial efficacy.2 In the trial by Llanos-Cuentas et al. (Jan. 17 issue)3 on the prevention of relapse of P. vivax malaria, we note that the reported percentages of patients in whom treatment with either primaquine or tafenoquine had failed were similar to percentages of predicted CYP2D6 reduced-function phenotypes in comparable geographic or . . .
Original languageEnglish
Pages (from-to)1875-1876
Number of pages1
JournalNew England Journal of Medicine
Volume380
DOIs
Publication statusPublished - 09 May 2019

Fingerprint

Dive into the research topics of 'Tafenoquine versus primaquine to prevent relapse of <i>Plasmodium vivax</i> malaria'. Together they form a unique fingerprint.

Cite this